Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 55

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 55
---
 connection with a change in control |     |                                               | 1,460,000 |     |             | 1,022,000 |     |        | 9,307,724 |     |               | 11,789,724 |     |           |       |
| Eric Bjerkholt                                                                       |     | Termination without cause or with good reason |           |     |             |   375,000 |     |        |         — |     |               |  1,396,498 |     | 1,771,498 |       |
| Termination without cause or with good reason in connection with a change in control |     |                                               |   750,000 |     |             |   337,500 |     |        | 3,148,284 |     |               |  4,235,784 |     |           |       |
| Peter Radovich                                                                       |     | Termination without cause or with good reason |           |     |             |   412,500 |     |        |         — |     |               |  1,743,235 |     | 2,155,735 |       |
| Termination without cause or with good reason in connection with a change in control |     |                                               |   825,000 |     |             |   412,500 |     |        | 3,270,913 |     |               |  4,508,413 |     |           |       |
| Joanne Quan, M.D.                                                                    |     | Termination without cause or with good reason |           |     |             |   375,000 |     |        |         — |     |               |    516,875 |     |   891,875 |       |
| Termination without cause or with good reason in connection with a change in control |     |                                               |   750,000 |     |             |   337,500 |     |        | 2,647,875 |     |               |  3,735,375 |     |           |       |

(1) In the event of termination without cause or with good reason, represents continued payment of base salary in accordance with our current payroll practices for 12 months for Mr. Peetz and nine months for the other named executive officers. In the event of

#### Mirum Pharmaceuticals2025 Proxy Statement45

#### TABLE OF CONTENTS

#### Executive Compensation
termination without cause or